Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arbaclofen extended release - RVL Pharmaceuticals

Drug Profile

Arbaclofen extended release - RVL Pharmaceuticals

Alternative Names: Arbaclofen extended release tablets (AERT) - RVL Pharmaceuticals; Ontinua ER; OS-440

Latest Information Update: 11 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Osmotica Pharmaceutical
  • Developer RVL Pharmaceuticals
  • Class Aminobutyric acids; Behavioural disorder therapies; Gastrokinetics; Muscle relaxants; Small molecules
  • Mechanism of Action GABA B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Muscle spasticity
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Muscle spasticity
  • No development reported Opioid-related disorders

Most Recent Events

  • 11 Dec 2024 No development reported - Phase-III for Muscle spasticity in Croatia (PO)
  • 28 Jun 2022 No recent reports of development identified for phase-I development in Opioid-related-disorders in USA (PO, Tablet)
  • 28 Feb 2022 RVL Pharmaceuticals has patent protection for Arbaclofen extended release in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top